

Gene Section

Mini Review

TMPRSS2 (transmembrane protease, serine 2)

Youngwoo Park

Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea (YP)

Published in Atlas Database: March 2010

Online updated version : <http://AtlasGeneticsOncology.org/Genes/TMPRSS2ID42592ch21q22.html>

DOI: 10.4267/2042/44922

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2010 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Other names: FLJ41954, PP9284, PRSS10

HGNC (Hugo): TMPRSS2

Location: 21q22.3

DNA/RNA

Description

TMPRSS2 gene approximately extends 43.59 kb-long on chromosome 21 in the region q22.3, containing 14 exons.

Transcription

Two alternative splicing variants have been described, producing transcripts of 3.25 kb and 3.21 kb, respectively.

Protein

Description

TMPRSS2 is a 492 amino acid type II transmembrane serine proteases (TTSPs) which are expressed at the cell surface and are thus ideally located to regulate cell-cell and cell-matrix interactions.

Expression

TMPRSS2 is expressed in normal and diseased human tissues. Especially, TMPRSS2 is highly expressed in small intestine, but also in lower levels in several other tissues. Also expressed in prostate, colon, stomach and salivary gland.

Localisation

Subcellular location: Cell membrane; Single-pass type II membrane protein.

Activated by cleavage and secreted.


Function


This gene was demonstrated to be up-regulated by androgenic hormones in prostate cancer cells and down-regulated in androgen-independent prostate cancer tissue. To containing intra- and extracellular domains, TMPRSS2 could work as a receptor for specific ligand(s) mediating signals between the environment and the cell. TMPRSS2 has been proposed to regulate epithelial sodium currents in the lung through proteolytic cleavage of the epithelial sodium channel and inflammatory responses in the prostate via the proteolytic activation of PAR-2.

Homology


TTPs (type II transmembrane serine proteases) contain an integral transmembrane domain and remain cell-surface-associated, even after proteolytic activation of the protease zymogen. Human TTSPs, which consists of 17 members, were grouped into four subfamilies based on similarity in domain structure and phylogenetic analysis of the serine protease domains, namely the matriptase, corin, hepsin/TMPRSS and HAT/DESC subfamilies.

TMPRSS2 Gene in genomic location





TMPRSS2 is a 492 amino acid single-pass type II membrane protein. It contains a Serine protease domain (aa 255-492) of the S1 family, followed by a Scavenger receptor cysteine-rich domain (SRDR, aa 149-242) of group A; an LDL receptor class A (LDLRA, aa 113-148) domain forms a binding site for calcium; a predicted transmembrane domain (aa 84-106). Letters H, D and S in the serine protease domain indicate the position of the three catalytic residues histidine, aspartate and serine, respectively.



Multidomain structure of human TTSPs. Human TTSPs were grouped into four subfamilies based on similarity in domain structure and phylogenetic analysis of the serine protease domains, namely the matriptase, corin, hepsin/TMPRSS and HAT/DESC subfamilies. Consensus domains are shown below. Each diagram was drawn using the web-based SMART software (<http://smart.embl-heidelberg.de>) with TTSP amino acid sequences obtained from GenBank.

Abbreviations: CUB, CIs/Clr, urchin embryonic growth factor and bone morphogenic protein-1 domain; DESC1, differentially expressed squamous cell carcinoma gene 1; FRZ, frizzled domain; HAT, human airway trypsin-like protease; LDLA, low-density lipoprotein receptor domain class A; MAM, a meprin, A5 antigen and receptor protein phosphatase m domain; MSPL, mosaic serine protease long-form; Polyserase-1, polyserine protease-1; SEA, a single sea urchin sperm protein, enteropeptidase, agrin domain; SR, scavenger receptor cysteine-rich domain; TM, transmembrane domain. Letters H, D and S in the serine protease domain (active) indicate the position of the three catalytic residues histidine, aspartate and serine, respectively. Letter A in the serine protease domain (inactive) indicates a serine to alanine exchange.

Implicated in

Prostate cancer


Prognosis

TMPRSS2 was originally reported to be a small intestine-associated serine protease. Later,

however, its gene turned out to be expressed mainly in the prostate in an androgen dependent manner.

In the prostate adenocarcinoma, TMPRSS2-EGR fusion mRNAs is highly expressed. Because of its location on the surface of prostatic cells, TMPRSS2 is a potential new diagnostic marker for prostate cancer.

Breakpoints



References

Paoloni-Giacobino A, Chen H, Peitsch MC, Rossier C, Antonarakis SE. Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. *Genomics*. 1997 Sep 15;44(3):309-20

Vaarala MH, Porvari K, Kyllönen A, Lukkarinen O, Vihko P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. *Int J Cancer*. 2001 Dec 1;94(5):705-10

Vaarala MH, Porvari KS, Kellokumpu S, Kyllönen AP, Vihko PT. Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues. *J Pathol*. 2001 Jan;193(1):134-40

Bugge TH, Antalis TM, Wu Q. Type II transmembrane serine proteases. *J Biol Chem*. 2009 Aug 28;284(35):23177-81

Choi SY, Bertram S, Glowacka I, Park YW, Pöhlmann S. Type II transmembrane serine proteases in cancer and viral infections. *Trends Mol Med*. 2009 Jul;15(7):303-12

Barwick BG, Abramovitz M, Kodani M, Moreno CS, Nam R, Tang W, Bouzyk M, Seth A, Leyland-Jones B. Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. *Br J Cancer*. 2010 Feb 2;102(3):570-6

This article should be referenced as such:

Park Y. TMPRSS2 (transmembrane protease, serine 2). *Atlas Genet Cytogenet Oncol Haematol*. 2010; 14(12):1163-1165.
